Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva Reports Strong Q1 2026 Results, Advances Pipeline, and Acquires Emalex

Teva Pharmaceutical Industries Ltd. reported Q1 2026 revenues of approximately $4.0 billion, a 2% increase in U.S. dollars year-over-year, though a 3% decrease in local currency. Non-GAAP diluted EPS reached $0.53, and free cash flow was $188 million. This performance was primarily driven by significant growth in key innovative brands like AUSTEDO, AJOVY, and UZEDY, which collectively grew 41% in local currency, offsetting lower generic revenues from lenalidomide capsules. Teva also highlighted pipeline advancements, including positive Phase 2b data for duvakitug in UC/CD and FDA acceptance of the olanzapine LAI NDA. The company announced the acquisition of Emalex Biosciences, adding NDA-ready ecopipam for Tourette syndrome, and maintained its 2026 financial outlook, adjusted for the Emalex transaction.

• Teva's Q1 2026 revenues reached $4.0 billion, marking a 2% increase in U.S. dollars year-over-year. This was largely propelled by its innovative portfolio, with AUSTEDO, AJOVY, and UZEDY collectively growing 41% in local currency, contributing significantly to the company's financial profile shift. Despite a 16% decrease in global generics revenues, mainly due to increased competition for lenalidomide capsules, the overall non-GAAP diluted EPS stood at $0.53, reflecting disciplined execution of the 'Pivot to Growth' strategy.
• Teva made significant progress in its late-stage pipeline, including positive Phase 2b maintenance data for duvakitug in ulcerative colitis and Crohn’s disease, positioning it as a potential 'best-in-class' anti-TL1A. The FDA also accepted the New Drug Application for olanzapine LAI for schizophrenia, with a Q4 2026 launch anticipated. Furthermore, biosimilars are becoming a crucial growth driver, with PONLIMSI™ receiving FDA approval as a biosimilar to Prolia® and applications for a Xolair® biosimilar accepted by both the U.S. FDA and the European Medicines Agency (EMA).
• Teva announced the acquisition of Emalex Biosciences, which will add ecopipam, an NDA-ready, first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome, to its neuroscience pipeline. This acquisition is expected to close by Q3 2026 and accelerates Teva’s 'Pivot to Growth' strategy. The company maintained its 2026 business outlook, projecting revenues between $16.4 - $16.8 billion and non-GAAP diluted EPS of $1.91 - $2.11, adjusted to reflect the Emalex transaction's impact.

Teva's Strategic Pivot: Innovation Drives Growth Amidst Generic Headwinds

Teva's latest financial report paints a clear picture of a pharmaceutical company actively navigating a strategic transformation. The robust growth of its innovative brands, AUSTEDO, AJOVY, and UZEDY, is not merely a financial highlight but a testament to a deliberate pivot away from a reliance on generic revenues, which are increasingly susceptible to market erosion, as evidenced by the decline in generic lenalidomide sales. Lenalidomide, while a cornerstone in multiple myeloma treatment and even showing promise in rare diseases like Rosai-Dorfman, faces intense generic competition, underscoring the imperative for Teva's branded portfolio to perform.

AJOVY (fremanezumab) stands out as a key growth engine. Clinical literature consistently demonstrates its efficacy and favorable tolerability profile in migraine prevention, particularly for patients who have failed multiple prior therapies. Its ability to significantly reduce migraine days and improve disability scores, with a quarterly dosing option, positions it strongly against competitors. However, the broader market context reveals a challenge: while effective, CGRP monoclonal antibodies like fremanezumab are costly, and some analyses suggest they may not be as cost-effective as older, cheaper oral medications like topiramate in certain healthcare systems. This necessitates a nuanced market access strategy to ensure broad patient reach.

Looking ahead, the FDA's acceptance of the olanzapine long-acting injectable (LAI) NDA represents a significant pipeline advancement. Oral olanzapine is a well-established antipsychotic, but adherence remains a major hurdle in managing chronic conditions like schizophrenia and bipolar disorder. An LAI formulation could dramatically improve treatment consistency, potentially leading to fewer relapses and hospitalizations. However, the known metabolic side effects of olanzapine, including elevations in cholesterol, triglycerides, and body weight, will require careful patient selection and monitoring, even with improved adherence. The recent acquisition of Emalex Biosciences, bringing NDA-ready ecopipam for Tourette syndrome, further signals Teva's commitment to expanding its specialized CNS footprint. This move into a new, high-unmet-need indication diversifies its portfolio and provides a fresh avenue for future growth, reinforcing the company's strategic shift towards innovation-driven value.